{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+hematopoietic+progenitor+cell+%28PBPC%29+transplant&page=2", "query": { "intervention": "Peripheral blood hematopoietic progenitor cell (PBPC) transplant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 156, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+hematopoietic+progenitor+cell+%28PBPC%29+transplant&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+hematopoietic+progenitor+cell+%28PBPC%29+transplant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T10:01:52.131Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00303836", "title": "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303836" }, { "nct_id": "NCT01936090", "title": "Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Autologous Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08", "completion_date": "2018-02-16", "has_results": false, "last_update_posted_date": "2018-05-24", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01936090" }, { "nct_id": "NCT00052520", "title": "Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "staining method", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2002-09", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052520" }, { "nct_id": "NCT00003838", "title": "Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Acute Myelogenous Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "T-cell replete PBPC allograft", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 202, "start_date": "1999-04-15", "completion_date": "2020-06-18", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003838" }, { "nct_id": "NCT00988715", "title": "Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Pretargeted Radioimmunotherapy", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-04-21", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-30", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00988715" }, { "nct_id": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017381" }, { "nct_id": "NCT00186628", "title": "Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Mast-Cell", "Mantle-cell Lymphoma" ], "interventions": [ { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Anti-thymoglobulin, rabbit (ATG, rabbit ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenylate mofetil", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 36, "start_date": "2005-06", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186628" }, { "nct_id": "NCT00036738", "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Blastic Phase", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase of Disease", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Disease" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Therapeutic Allogeneic Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 28, "start_date": "2001-07-13", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 3, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036738" }, { "nct_id": "NCT00061568", "title": "Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Congenital Hemolytic Anemia", "Sickle Cell Disease" ], "interventions": [ { "name": "Peripheral blood hematopoietic progenitor cell (PBPC) transplant", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Peripheral blood hematopoietic progenitor cell Apheresis", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 130, "start_date": "2004-07-16", "completion_date": "2028-01-20", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061568" }, { "nct_id": "NCT00008177", "title": "Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Anemia With Ringed Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "iodine I 131 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 79, "start_date": "1999-07-27", "completion_date": "2010-12-15", "has_results": false, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-10-12T10:01:52.131Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008177" } ] }